OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$8.73
-0.03 (-0.34%)
▼
5d:
-5.83%
30d:
-27.37%
90d:
-36.74%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: OCS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: OCS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $8.73, which is considered oversold relative to its 30-day fair value range of $9.45 to $12.13.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is currently testing key support at $8.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OCS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.58 (+319.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is currently testing key support at $8.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OCS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.58 (+319.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.45 -
$12.13
Company Quality Score
43/100
(HOLD)
Options IV Signal
40th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 40th percentile)
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 319.0% below Wall St target ($36.58)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.45 -
$12.13
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.53
(17.5%)
Support & Resistance Levels
Support Level
$8.53
Resistance Level
$10.84
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.30
Wall Street Target
$36.58
(+319.0%)
Revenue Growth (YoY)
18.8%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 2:11 AM
Data refreshes hourly during market hours. Next update: 2:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 52 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
